A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL

This study is testing a combination of two cancer drugs — GFH009 (a CDK4/6 inhibitor) and zanubrutinib (a BTK inhibitor) — in people with a type of aggressive blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older - You have been diagnosed with relapsed or refractory DLBCL or a related large B-cell lymphoma - You have already tried 2 to 4 previous treatment regimens, including at least one that contained both an anthracycline (a type of chemotherapy) and rituximab - You are not a suitable candidate for a stem cell transplant - You have at least one measurable tumor **You may NOT be eligible if...** - Your lymphoma has not yet been treated - You have only tried one previous treatment - You are eligible for and willing to undergo a stem cell transplant Talk to your doctor to see if this trial is right for you.